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Abstract
Background: Patients’ pre-operative health and physical function is known to influence their post-operative
outcomes. In patients with knee osteoarthritis, pharmacological and non-pharmacological options are often not
optimised prior to joint replacement. This results in some patients undergoing surgery when they are not as fit as
they could be. The aim of this study is to assess the feasibility and acceptability of a pre-operative package of non-
operative care versus standard care prior to joint replacement.
Methods/design: This is a multicentre, randomised controlled feasibility trial of patients undergoing primary total
knee replacement for osteoarthritis. Sixty patients will be recruited and randomised (2:1) to intervention or standard
care arms. Data will be collected at baseline (before the start of the intervention), around the end of the
intervention period and a minimum of 90 days after the planned date of surgery. Adherence will be reviewed each
week during the intervention period (by telephone or in person). Participants will be randomised to a pre-operative
package of non-operative care or standard care. The non-operative care will consist of (1) a weight-loss programme,
(2) a set of exercises, (3) provision of advice on analgesia use and (4) provision of insoles. The intervention will be
started as soon as possible after patients have been added to the waiting list for joint replacement surgery to take
advantage of the incentive for behavioural change that this will create. The primary outcomes of this study are
feasibility outcomes which will indicate whether the intervention and study protocol is feasible and acceptable and
whether a full-scale effectiveness trial is warranted.
The following will be measured and used to inform study feasibility: rate of recruitment, rate of retention at 90-day
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follow-up review after planned surgery date, and adherence to the intervention estimated through review
questionnaires and weight change (for those receiving the weight-loss aspect of intervention). In addition the
following information will be assessed qualitatively: analysis of qualitative interviews exploring acceptability,
feasibility, adherence and possible barriers to implementing the intervention, and acceptability of the different
outcome measures.
Discussion: The aims of the study specifically relate to testing the feasibility and acceptability of the proposed
effectiveness trial intervention and the feasibility of the trial methods.
This study forms the important first step in developing and assessing whether the intervention has the potential to
be assessed in a future fully powered effectiveness trial. The findings will also be used to refine the design of the
effectiveness trial.
Trial registration: ISRCTN registry, ID: ISRCTN96684272. Registered on 18 April 2018.
Background
The lifetime risk of knee osteoarthritis (OA) is 45% [1].
OA is the fastest growing cause of disability worldwide
[2] and predicted to be the fourth leading cause of dis-
ability by 2020. Non-operative treatments, such as exer-
cise, orthoses, analgesics and weight loss, are known to
benefit patients with OA [3]. Patients with more severe
OA are referred to secondary care for consideration of
joint replacement surgery. Around 85,000 total knee
arthroplasties (TKA) are performed annually in the UK
[4]. Dissatisfaction with outcome is reported in around
20% of these cases [5, 6].
Patients’ pre-operative health and physical function
is known to influence their post-operative outcomes.
In patients with knee OA, pharmacological and non-
pharmacological options are often not optimised
prior to joint replacement. This results in some pa-
tients undergoing surgery when they are not as fit as
they could be.
The overall aim of this project is to develop a complex
intervention and an implementable package of care for
patients listed for total knee replacement with the aims
of improving post-operative outcomes and reducing
complication risks. The aims of the study specifically re-
late to testing the feasibility and acceptability of the pro-
posed effectiveness trial intervention and the feasibility
of the trial methods.
This study aims to take advantage of the incentive for be-
havioural change in patients with osteoarthritis (OA) who
have been placed on the waiting list for orthopaedic surgery,
to obtain a durable alteration in the patients’ weight and ex-
ercise level. Non-operative treatments, such as exercise,
orthoses, analgesics and weight loss, are known to benefit
patients with OA [3] but are often not optimised prior to
joint replacement. We postulate that the reduction in weight
and increased activity coupled with an appropriate analgesia
review and attention to footwear in the pre-operative win-
dow will result in a sustained improvement in the patient’s
health-related quality of life following knee replacement.
Exercise
The amount of exercise that osteoarthritic patients at-
tending orthopaedic clinics carry out is very variable, yet
there is good evidence that exercise (such as walking,
swimming and cycling) reduces pain and improves phys-
ical function in patients with knee OA [7, 8]. The pa-
tients in this study are at the stage of listing for knee
replacement and for them (unlike the early OA group
for whom OARSI guidelines have been developed) the
most efficacious exercise is muscle strengthening as this
can enhance functional ability such as climbing stairs.
Footwear
Shoes which have a thick shock-absorbing sole are con-
sidered most suitable for patients with lower-limb OA.
In particular, there is evidence that in patients with knee
OA, the use of shoes with shock-absorbing insoles for 1
month reduces pain and improves physical function [9].
Analgesics
Many patients are not keen on taking strong painkillers,
and compliance with OA pharmacological treatment is
around 50% [10]. However, for mild to moderate pain,
paracetamol can be effective. In addition, there is evi-
dence that topical non-steroidal anti-inflammatory drugs
(NSAIDs) may help relieve pain in knee and hand OA, yet
many patients have not tried a range of simple analgesics.
Weight loss
Obesity and being overweight are known to impair mo-
bility and activity [11, 12]. Patients frequently have not
lost weight prior to being listed for surgery and often
have actually gained weight. There is evidence that for
those who have knee OA being overweight can make
symptoms worse for those who have knee OA [13].
In primary care, the effectiveness for patients with
knee OA of weight-loss regimens on body weight, pain
and/or physical function has been demonstrated in pro-
grammes delivered as weekly supervised sessions for a
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range of 8 weeks to 2 years [14–19]. In secondary care,
in a study in New Zealand, where the waiting list times
typically exceed 1 year, patients with a Body Mass Index
(BMI) of over 40 were seen by a dietician. Surgery was
withheld until the BMI was less than 40. Fifty-eight per-
cent of patients lost weight [20]. A further study carried
out in Denmark on osteoarthritic patients has demon-
strated that a significant weight loss can occur in 8
weeks [21] and that a greater initial weight loss improves
long-term maintenance of the reduction in weight.
Behavioural change
The package of care has a behavioural component which
draws on Social Cognitive Theory, the Health Belief
Model and Control Theory. It incorporates a number of
evidence-based behaviour-change strategies to help
people to change their behaviour initially and maintain
this in the longer term, particularly in relation to the
four elements of the intervention; adherence to medica-
tion, use of insoles, diet and physical activity. The key
behaviour-change strategies include goal-setting, plan-
ning, self-monitoring and dealing with relapse. The
intervention will also address key motivational aspects.
Behavioural changes are often difficult to achieve in pri-
mary care [22]. However, a recent cluster-randomised
trial [23] has demonstrated that smoking-cessation ther-
apy given during a hospital in-patient episode had a
much higher success rate suggesting that capitalising on
the secondary-care episode could be an ideal time to
change patients’ behaviour; especially if it is linked to
the impending surgery.
The aim of the current research is to take advantage of
this incentive for behaviour change in patients with OA at-
tending orthopaedic clinics so that there is a durable
change in the patients’ weight and exercise level, which,
coupled with appropriate analgesia and insoles, could
relieve the morbidity of their OA and improve outcomes
following surgery. Recent evidence suggests that behaviour-
change interventions may improve patient compliance with
these non-surgical interventions and thus their success
[23]. By optimising the non-operative treatment prior to
surgery it may be possible to improve outcomes, such as
knee pain and function, following surgery, reduce post-
operative complications and at the same time improve the
health-related quality of life of the patients.
Even though the proposed package of care of non-
surgical interventions is recommended for this popula-
tion, the delivery of, and adherence to, these interven-
tions is variable. As recommended by the Medical
Research Council guidance on the development and
evaluation of complex interventions [24], we aim to
carry out a feasibility study collecting both quantitative
and qualitative data prior to embarking on a fully pow-
ered effectiveness randomised controlled trial (RCT).
This study forms the important first step in developing
and assessing whether the intervention has the potential
to be assessed in a future fully powered effectiveness
trial. The findings will also be used to refine the design
of the effectiveness trial.
Methods/design
Objectives
The objective is to test the feasibility of the study
methods and intervention delivery as well as the accept-
ability of the intervention in preparation for a fully pow-
ered effectiveness trial.
We aim to evaluate this by:
1. Investigating recruitment and retention
2. Investigating the feasibility and acceptability of the
intervention (including assessment of the feasibility
and acceptability of the intervention across a range
of BMI values)
3. Exploring the barriers and facilitators to
implementing the intervention
4. Assessing the feasibility and acceptability of
different outcome measures
5. Estimating the variability in the key outcome
measures, to inform the sample size calculations for
the effectiveness trial
6. Estimating key cost-drivers to inform the design of
a future economic evaluation
Endpoints and process measures
Primary endpoint
The primary endpoint is whether the intervention and
study protocol is feasible and acceptable and whether a
full-scale effectiveness trial is warranted.
The following will be measured and used to inform
study feasibility:
1. Rate of recruitment
2. Rate of retention at follow-up review after planned
surgery date
3. Adherence to the intervention estimated through
review questionnaires and weight change (for those
receiving the weight-loss aspect of the intervention)
In addition the following information will be assessed
qualitatively:
1. Qualitative interviews (with participants,
researchers and clinical staff) exploring
acceptability, feasibility, adherence and possible
barriers to implementing the intervention
2. Acceptability of the different outcome measures
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In addition to the above, a process evaluation will be
carried out to explore in detail the way in which the
intervention operates to produce outcomes. The evalu-
ation will be conducted based on Medical Research
Council guidelines for process evaluations of complex
interventions and will examine the following elements:
(1) context; (2) fidelity of the intervention; (3) exposure
to the intervention; (4) reach; (5) recruitment and reten-
tion; (6) contamination; (7) the control arm; and (8) and
mechanisms of impact. A logic model will be developed
and tested as part of the process evaluation. A protocol
for process evaluation will be prepared as a separate
document.
Secondary endpoints
In the feasibility study we will monitor change for a
minimum of 90 days after the planned surgery date in
the outcomes we are interested in evaluating in the ef-
fectiveness trial. These are:
Change in:
1. Western Ontario and McMaster Universities
Osteoarthriis Index (WOMAC) sub-scores
2. Change in Oxford Knee Score (OKS), EuroQol five
dimensions questionnaire (EQ-5D) score, timed get-
up-and-go test and self-efficacy questionnaire scores
3. Clinical outcomes following surgery (including
routine complications)
4. Management of patient comorbidities
5. Patient satisfaction with knee pain and function
6. Identification of key cost drivers
Study design
The study is a multicentre, randomised controlled feasi-
bility trial which aims to assess the feasibility of running
a pivotal randomised controlled trial (RCT) of a pre-
operative package of non-operative care versus standard
care prior to joint replacement.
We aim to recruit 60 participants (split between Edin-
burgh and Leeds sites). Recruitment is planned to take
place over a 6-month period with a follow-up conducted
for a minimum of 90 days after the planned surgery date.
Patients recently added to the waiting list for knee re-
placement surgery due to osteoarthritis will be
approached about the study by a member of the clinical
team at the outpatient clinic visit where the decision to
proceed to knee surgery has taken place.
All participants will be seen for a baseline visit, where
they will be randomised. Depending on the result of ran-
domisation, patients will be asked to follow standard
care or the intervention until their planned date of sur-
gery (duration of intervention will depend on when knee
surgery is due to take place). All participants will be seen
in clinic at the end of the intervention period for a final
review (pre-surgery) and a minimum of 90 days after the
planned date of surgery. Participants in the intervention
arm will also be reviewed regularly for the duration of
the intervention to assess adherence.
A process evaluation (as described in ‘Section 2’) will
be conducted.
Study population
Number of participants
Feasibility trial
Sixty participants will be recruited across two sites
(roughly 30 in Edinburgh and 30 in Leeds) and random-
ized (2:1) to the intervention or standard care. It is im-
portant that both sites are involved in the feasibility
study to establish that the design can fit with different
service delivery models, to determine the generalisability
of the intervention and the potential to expand to a mul-
ticentre effectiveness study.
Participant recruitment is planned to take place over a
6-month period and follow-up will be conducted a mini-
mum of 90 days after the planned date of knee replace-
ment surgery.
Participants will be stratified to ensure that we address
the aim of testing the feasibility of recruiting people with
a range of BMI values.
Process evaluation
Patients will be sampled purposively across a range of
ages and trial participation status (refused to participate,
agreed and retained to follow-up, agreed but did not
complete the intervention) and approached to partici-
pate in the qualitative interviews. It is anticipated that
up to 30 interviews will be required (split between Edin-
burgh and Leeds); data collection will continue until a
point of saturation has been reached. All health care
practitioners involved in the delivery of the intervention
will be interviewed as well as up to five staff at each of
the sites where the intervention is being delivered, in-
cluding members of the participants clinical care team.
Interviews will be conducted face to face and also by
telephone according to the preference of the interviewee.
Participants will also be invited to provide consent to
allow recording of study reviews (where the research
nurse is happy to do so) which will be analysed as part
of the process evaluation.
Inclusion criteria
For participants:
1. Undergoing a knee arthroplasty for OA
2. Participant meets at least one of the following
threshold criteria:
(a) BMI ≥ 30 kg/m2
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(b) Inability to perform straight-leg raise (no exten-
sor lag) or patient-reported ‘giving way’
(c) Not taking an appropriate level of analgesia
(d) Not using shock-absorbing footwear
3. Participants are able to consent and willing to
comply with the study protocol
4. Sufficient time for the intervention to be delivered
before the planned date of surgery and for the
follow-up appointment to be conducted after the
planned date of surgery
5. Aged 18–85 years (inclusive)
For staff:
1. Staff members to be interviewed should be
members of the research team involved in
delivering the intervention to participants or
members of the clinical care team/associated
personnel at the site where the intervention is being
delivered
Exclusion criteria
For participants:
1. Patients undergoing revision knee arthroplasty or
fully constrained knee arthroplasty
2. Knee replacement for a diagnosis other than OA
3. Patients with a second contralateral procedure
planned within the study timeframe
4. Procedures done purely for pain relief (such as for
patients with no walking capacity)
5. Patients involved in another research study
containing elements of behaviour change related to
diet, physical activity and other study elements
6. Patients currently under active review with a
clinician for physiotherapy
7. Participants who cannot understand verbal
explanations or written information given in English
8. Pregnant until > 4 months post-partum;
breastfeeding
Additional exclusion criteria applicable to participants
eligible for the weight-loss aspect of the intervention:
1. Patients who have recently lost a significant amount
of weight (> 5 kg in the preceding 3 months) or who
are already on a specialised diet
2. Patients with:
a. Insulin-dependent diabetes
b. Brittle type-2 diabetes which is managed in sec-
ondary care (confirmed by recent glycated
haemoglobin (HbA1c) measurement if available)
c. Patients with moderate or severe retinopathy
3. Patients taking four or more anti-hypertensive
agents
4. Patients with active mental illness: severe
depression, bipolar disorders, schizophrenia or
other psychotic disorders
5. Myocardial infarctions or stroke within the previous
3 months
6. Heart failure of grade III New York Heart
Association or more severe
7. Porphyria
8. Substance abuse, e.g. drugs, alcohol
9. Eating disorder accompanied by purging (through
laxative abuse or induced vomiting)
10. Previous bariatric surgery or scheduled bariatric
surgery
11. Angina, arrhythmia, including atrial fibrillation or
prolonged QT syndrome
12. Taking monoamine-oxidase inhibitor (MAOI)
medication
13. Taking anticoagulant medication (e.g. warfarin)
14. Taking varenicline (smoking-cessation medication)
15. Chronic renal failure of stage 4 or 5 (as indicated by
a recent estimated glomerular filtration rate (eGFR)
reading of < 30 ml/min/1.73m2)
16. Patients:
a. With active liver disease (except non-alcoholic
fatty liver disease (NAFLD)
b. With a history of hepatoma
c. Within 6 months of onset of acute hepatitis
17. People having active treatment for cancer other
than skin cancer treated with curative intent by
local treatment only, or people taking hormonal or
other long-term secondary prevention treatment
after initial cancer treatment
18. Active treatment or investigation for possible or
confirmed gastric or duodenal ulcer; maintenance
treatment with acid suppression is not a
contraindication
19. Displaying symptoms associated with gallstones in
the last 3 months
20. Not taking a proton-pump inhibitor if taking orally
administered ibuprofen
Patients with type-2 diabetes being managed by their
GP can be included if they are taking orally administered
agents only or are diet-controlled type-2 diabetics.
Patients who have not responded to previous conser-
vative management will not be excluded, indeed these
patients are particularly interesting to see why their pre-
vious management failed, as this may have been due to a
compliance problem.
Patients should be wiling to undertake the aspects of
the package that they ‘qualify’ for based on the inclusion
thresholds. Patients who trip several of the inclusion
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thresholds but meet the exclusion criteria for one or
more will not be included.
For staff:
There are no exclusion criteria for staff.
Co-enrolment
Co-enrolment will be permitted with other studies pro-
vided that the burden is acceptable to the participants
and the study intervention does not involve any ele-
ments of behaviour change related to diet, physical activ-
ity and other study elements. Researchers must take care
to not over-burden participants with requests to take
part in research studies. Co-enrolment can only occur
with studies where agreement has been obtained from
the Chief Investigators (CIs) for each study.
Participant selection and enrolment
Identifying participants
Recruitment will be from the outpatient clinic where the
decision to proceed to total knee replacement is made.
A member of the clinical team will highlight the trial to
the patient and, if interested in hearing more, the patient
will be invited to complete a ‘Consent to Researcher
Contact’ form and be provided with a patient informa-
tion sheet. If it is known that a patient has type-2 dia-
betes and/or hypertension and appears to be eligible for
the weight-loss aspect of the intervention, the ‘GP con-
sent’ section of this form should also be completed (this
will allow the research team to contact the patient’s GP
in advance of randomisation to obtain consent regarding
potential medication changes should the patient be ran-
domised to the intervention arm). The patient will be
given sufficient time to consider the study information,
typically at least 24 h; however, contact may be made be-
fore this with the agreement of the patient. A member
of the research team will discuss the study further with
the patient and assess patient eligibility. Posters will also
be placed in orthopaedic outpatient clinic areas for pa-
tients to highlight the study to site staff. Consent for the
research team to contact the patient regarding the study
may also be documented in a clinic letter from the
consultant.
All staff delivering the intervention at sites will be
invited to take part in an interview. A selection of
staff involved in the care of individuals being seen at
the outpatient clinic (including, but not limited to,
orthopaedic surgeons doing knee replacement sur-
gery, outpatient clinical staff dealing with knee re-
placement patients, managers involved in care
delivery) at the centres taking part in the study will
be invited to take part in an interview. These staff
will be approached by members of the research team
and provided with an information sheet and invited
to complete a Consent to Contact Form. A sampling
frame will be used which will include ensuring
spread across the Leeds and Edinburgh sites and a
range of relevant specialties and job roles.
Consenting participants
If a patient agrees to take part in the study, a study visit
will be arranged. Patient eligibility will be confirmed and
written informed consent taken by a suitably qualified
member of the research team.
Patients who are not interested in taking part in
the study will be asked to consider taking part in an
interview with the qualitative researcher only. Those
that agree and would prefer the interview to be car-
ried out over the telephone will be asked to provide
their consent orally at the time of interview which
will be audio-recorded. Participants who prefer to
conduct the interview in person will be asked to
provide written informed consent.
Clinical care team staff/associated personnel and the
health care practitioners delivering the intervention who
agree to be interviewed as part of the study will also be
asked to provide either audio-recorded consent or writ-
ten informed consent depending on their preference for
interview.
Withdrawal of study participants
Participants are free to withdraw from the study at any
point or a participant can be withdrawn by the Investiga-
tor. If withdrawal occurs, the primary reason for with-
drawal will be documented on the patient’s Case Report
Form (CRF). If participants choose to have their data re-
moved from the analysis, this will be indicated on the
appropriate form.
Withdrawal from study treatment will be distinguished
from withdrawal from the study. Participants may
choose to discontinue their participation in aspects of
the intervention or study but remain active on the study
(for example, to participate in the interview). The as-
pects of the study that the participant is happy to con-
tinue taking part in will be documented.
Screening for eligibility
Participants will be identified and approached about the
study by a member of the clinical team at the outpatient
clinic where the decision to proceed to total knee re-
placement is made and then be formally screened by a
member of the research team. Members of the clinical
care team (or research team members, where it is locally
agreed that they are part of the clinical care team, under
the direct supervision of the site’s Principal Investigator
(PI)) will review identifiable information (e.g. medical
notes and clinic lists) to identify potential participants.
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They will not review or screen identifiable data that is
outside normal clinical practice.
Participant eligibility may be verified by the research
nurse. Confirmation of eligibility will be recorded within
the participants’ medical records.
Ineligible and non-recruited participants
Patients who are approached about the study but are
found to be ineligible or refuse to take part will be re-
corded on the screening log. Patients who are not inter-
ested in taking part in the study will be asked to
consider taking part in an interview with the qualitative
researcher only. The reason for refusal, if provided, or
ineligibility will be recorded on the screening log.
Randomisation
Randomisation procedures
The allocation ratio is 2:1 between the Intervention and
Standard Care treatment groups. Patients will be rando-
mised at the baseline visit. Following randomisation,
both the participant and the Investigator will be notified
of the assigned treatment allocation.
A stratified list will be used to randomise the partici-
pants to a treatment group. Participants will be stratified
by site and BMI band. BMI bands of < 30, ≥ 30 to < 35
and ≥ 35 will be employed. The stratified list will use
block sizes of 3 and 6. The blocks will be randomly gen-
erated. The following additional constraints will be
applied:
 At least one third of the participants recruited will
have a BMI in the range ‘≥ 30 and < 35’
 At least one third of the participants recruited will
have a BMI in the range ‘≥ 35’
Randomisation will be performed via a secure online
randomisation system, set up by the Edinburgh Clinical
Trials Unit, ensuring allocation concealment, and will be
undertaken by an appropriate delegated member of trial
team at study sites. In the event that the online random-
isation process cannot be accessed there is a telephone
back-up system available through the Edinburgh Clical
Trials Unit (ECTU) (during office hours), details of
which will be provided to the site teams.
Treatment allocation
Where a participant is randomised to the Intervention
treatment group, they will be allocated one or more of
the following aspects of the intervention. The aspects
they qualify for will depend on the threshold criteria
met.
 Analgesia
 Physical activity
 Weight-loss programme
 Insoles
Study arms
Eligible patients will be randomised (2:1) to either the
intervention or control arm. The duration of the inter-
vention will be determined based on when the patient is
due for surgery.
Intervention arm
A logic model detailing the programme theory and an
intervention manual for the study will be produced as
separate documents.
Patients randomised to the intervention arm will be
provided with the relevant elements of the package they
‘qualify’ for (listed below) by the research nurse deliver-
ing the intervention at the baseline visit.
Behaviour change
This is a fundamental ingredient of the intervention
which underlies the other aspects listed below. These
behaviour-change techniques utilised as part of this
intervention in relation to these different elements are;
goal-setting, self-monitoring, providing feedback, plan-
ning, barrier identification, problem-solving, engaging
social support and dealing with relapse.
Analgesia review
A member of the research team will review the use and
timing of appropriate topical and orally administered an-
algesics with the patient. If the participant meets the in-
clusion criteria related to analgesia usage, a member of
the research team will discuss advice in line with routine
clinical care regarding painkillers that may help with
pain related to knee osteoarthritis.
Physical activity
Participants who are unable to perform a straight-leg
raise (extensor lag) or report ‘giving way’ will be pro-
vided with exercises to do at home. The exercise pack-
age will be tailored to the individual patient based on
their pain symptoms experienced during physical activity
[25]. Strengthening exercise of the lower limb will be
targeted to facilitate enhanced functional activity with
daily tasks. The focal intervention will be quadriceps
muscle strengthening through a graded progression of
load and intensity (to target giving way/straight-leg-raise
lag symptoms). Specific parameters surrounding individ-
ual exercise selection, frequency, load and intensity will
vary with the patient’s ability and baseline strength [26].
Exercises will be performed at home without the need
for equipment. Additionally, the patient’s current levels
of physical activity will be reviewed and aerobic exercise
will be promoted as pain allows.
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Weight-loss programme
A weight management programme comprising a Low
Energy Liquid Diet (LELD) will be offered to all whose
BMI is > 30 kg/m2. The programme will utilise the
Counterweight-Plus programme and will comprise a
Total Diet Replacement (TDR) phase of 800 kcal/day for
8–12 weeks. For those participants receiving the weight-
loss intervention enough diet resource will be provided
for approximately 2 weeks and then replenished at the
fortnightly review visits with the local research team.
The Counterweight-Plus programme includes a LELD
and is an effective intervention [27, 28]. It is manualised
to maintain the fidelity of the intervention. Participants
offered the LELD will be given structured advice for the
period of the intervention. After the TDR phase, advice
and information on weight-loss maintenance and food
reintroduction will be provided. This aims to increase
the sustainability of the TDR, maximising the likelihood
that weight loss will be maintained after the 8–12 week
TDR phase [27, 28]. The local research team will discuss
the plan for food reintroduction with the participant
(this will be individualised based on the time available
before surgery) and will provide support around phased
food reintroduction to allow them to return to a normal
diet. To facilitate this, a minimum period of at least 1
week should be left between the end of the intervention
and the date of surgery. Depending on the time available
before surgery, some patients may progress to the
Weight Loss Maintenance phase. Advice on weight-loss
maintenance and support will be provided by the re-
search team.
Insoles
If patients are not already routinely using shock-
absorbing insoles or are deemed not to routinely wear
shoes with shock-absorbing soles, they will be provided
with shock-absorbing insoles. This component of the
intervention is supported by NICE and EULAR guide-
lines and will help minimise limitation from OA. It is
considered that minimising the restriction caused by OA
will help patients comply with physiotherapy and weight
reduction.
Delivery of the intervention
The intervention will be delivered by members of the re-
search team who have been trained accordingly. Partici-
pants will attend for a baseline assessment and provision
of the specific package of conservative interventions in-
cluding the behaviour-change component. Face-to-face
review sessions will take place at fortnightly intervals to
deliver relevant intervention components (including the
behaviour-change component) and to assess adherence
to the intervention and to re-supply the dietary resource.
Apart from the clinic-based reviews, the intervention
will be ‘home’ based for the intervention period. On the
weeks in between visits for the first 8–12 weeks, a mem-
ber of the research team at each centre will make weekly
review telephone calls to the participant to deliver rele-
vant intervention components (including the behaviour-
change component) and to assess adherence to the
intervention.
Participant compliance
Compliance with the randomisation allocation will be
assessed using data collected through review question-
naires and weight change (for those receiving the
weight-loss aspect of the intervention) for the purposes
of the study outcomes. Non-compliance with the rando-
mised allocation will not be recorded as a protocol devi-
ation and/or violation.
Medication changes related to the weight-loss programme
Participants with type-2 diabetes (being managed by their
GP) and/or hypertension who are randomised to the inter-
vention arm of the study and qualify for the weight-loss as-
pect of the study may find that the doses of drugs they
need to control their diabetes and high blood pressure need
to be reviewed. Research staff may discuss potential medi-
cation changes with participants and GPs (with participants’
consent). Further information and advice for research staff
will be provided in the study intervention manual and the
medication management plan. Decisions regarding medica-
tion changes are down to the individual participant’s situ-
ation and GP preference. A medication management plan
(which has been formulated from previous studies using
the Cambridge Weight Plan) will be agreed with these par-
ticipants’ GP before the intervention is started and will be
employed by site PIs (and sub-investigators delegated to
perform this task) when changes to medication are re-
quired. Site PIs (and/or sub-investigators delegated to per-
form this task) will be responsible for decisions made
regarding medication changes. GPs will be informed of
medication changes made by the PI. Hypertensive
participants’ blood pressure and diabetic participants’
blood glucose levels will be monitored at clinic visits.
In addition to the schedule outlined in ‘Section 7’,
diabetic participants with home blood glucose moni-
tors may be advised to monitor their blood glucose
levels at home as required.
Control arm
Participants in the control arm will receive usual local
standard care prior to total knee replacement at their
local treatment centre. Care received and any change in
the trial parameters (weight loss, analgesia usage, etc.) in
the control arm will be documented and evaluated to
determine any behaviour change in this arm brought
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about through the informed consent process or comple-
tion of study questionnaires.
Study assessments
An example summary of study assessments and visits is
provided in Table 1 and a schematic of the patient jour-
ney in Additional file 1 Figure S1.
Potential participants will be assessed against the in-
clusion and exclusion criteria as much as possible over
the telephone by a member of the research team to de-
termine eligibility. If deemed potentially eligible, partici-
pants will be invited to attend for a baseline visit.
Baseline visit (all participants)
Participants will be asked to provide their consent to
take part in the study. Participants will be assessed
against the inclusion and exclusion criteria to confirm
eligibility. Participants who are eligible for the weight-
loss aspect of the study will be asked to complete a
binge-eating scale questionnaire and eating-disorder
examination questionnaire to assess the presence of an
eating disorder. Participants eligible for the weight-loss
aspect of the intervention will be invited to try a sample
of the weight-loss product before randomisation. Basic
demographic details (including height, weight and blood
pressure measurements) and medical history will be col-
lected from all participants. A timed-get-up-and-go test
will be performed; this is the time that a person takes to
rise from a chair, walk 3 m, turn around, walk back to
the chair, and sit down and will be measured. The fol-
lowing questionnaires will also be completed: WOMAC,
OKS, EQ-5D, arthritis self-efficacy, pain self-efficacy
scale and a pain questionnaire. These questionnaires are
those proposed for use in the effectiveness trial. Partici-
pants will then be randomised.
Participants randomised to the control arm will receive
usual local standard care prior to total knee replacement
for the period between the start of intervention and their
planned date of surgery.
Participants randomised to the intervention arm will
be provided with whichever elements of the package
they ‘qualify’ for by a member of the research team. Par-
ticipants will receive the intervention for the period be-
tween the start of intervention and their planned date of
surgery. All services/interventions received in the control
group will be recorded.
Participants who are to receive the weight-loss aspect
of the intervention will be asked to complete an eating
self-efficacy scale questionnaire.
Participants with diabetes receiving the weight-loss as-
pect of the intervention will have blood glucose levels
checked at this visit using a blood glucose meter.
Telephone reviews (participants in the intervention arm)
Participants will be contacted by telephone every 2
weeks (± 3 days) by a member of the local research team
and a review assessing the participant’s general health
and adherence to the intervention will be completed.
Relevant intervention components (including the behav-
ioural component will also be delivered. These calls will
occur approximately every 2 weeks (starting on week 1)
after initiating the intervention until the end of the TDR
phase for participants on the weight-loss programme or
for 8–12 weeks for participants receiving the other as-
pects of the intervention (depending on the time avail-
able before surgery).
For participants with diabetes and/or hypertension, the
week-1 review telephone call will be a clinic visit in order
to measure blood pressure and blood glucose levels.
Clinic reviews (participants in the intervention arm)
Relevant intervention components (including the behav-
ioural component) will be delivered in person every 2
weeks (± 3 days) by a member of the local research team
and a review assessing the participants’ general health
and adherence to the intervention will be completed.
Participants will be asked to complete a pain question-
naire. These visits will occur approximately every 2
weeks (starting on week 2) after initiating the interven-
tion until the end of the intervention period. After the
end of the TDR phase for participants on the weight-loss
programme or after 8–12 weeks for participants receiving
the other aspects of the intervention (depending on the
time available before surgery), participants will be encour-
aged to come to clinic to complete these reviews; however,
they may be conducted by telephone if preferred.
At these clinic reviews, weight will be collected from
those participants receiving the weight-loss aspect of the
intervention. Blood pressure measurements will be col-
lected from all participants. Participants with diabetes
who are receiving the weight-loss aspect of the interven-
tion will have blood glucose levels checked at these visits.
For participants with diabetes and/or hypertension, the
week-1 review telephone call will be a clinic visit in order
to measure blood pressure and blood glucose levels.
A clinic review visit should be carried out at the end
of the TDR phase for those participants undertaking the
weight-loss programme where there is more than 1 week
available for food reintroduction. At this visit, advice
and information on food reintroduction will be provided.
The local research team will discuss the plan for food re-
introduction with the participant and support will be
provided around phased food reintroduction to allow
the participant to return to a normal diet before surgery.
A sample food reintroduction plan will be prepared as a
separate document; however, for each patient the plan
will be individualised based on the time available before
Simpson et al. Trials          (2020) 21:209 Page 9 of 16
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surgery. A period of at least 1 week should be left be-
tween the end of the TDR and the date of surgery to fa-
cilitate the food reintroduction process.
Weight-loss programme participants will be asked to
complete a binge-eating scale questionnaire and an
eating-disorder examination questionnaire at this end of
TDR and end of Food Reintroduction phases if a binge-
eating disorder was identified at the baseline visit and if
participants display issues with eating food while on TDR.
Depending on the time available before surgery, some
patients may progress to the Weight Loss Maintenance
phase. Patients who progress to this phase will be pro-
vided with appropriate advice on weight-loss mainten-
ance and supported by the study team until their
planned surgery date.
Final review (all participants)
Participants will complete a final study review at the
hospital 1 week (± 3 days) before the planned surgery
date. Patients in the control arm may have their Final
Review clinic visit aligned with their pre-admission clinic
visit where the pre-admission clinic visit is no more than
3 weeks before surgery. All services/interventions re-
ceived in the control group will be recorded.
Participants will complete a review assessing their gen-
eral health and adherence to the intervention. A timed-
get-up-and-go test will be performed in addition to the
following questionnaires: WOMAC, OKS, EQ-5D, arth-
ritis self-efficacy, pain self-efficacy scale, a pain question-
naire and an eating self-efficacy scale (for those
participants receiving the weight-loss aspect of the inter-
vention). Weight and blood pressure measurements will
be collected from all participants. Participants who have
undertaken the weight-loss aspect of the study will be
asked to complete a binge-eating scale questionnaire and
an eating-disorder examination questionnaire at the end
of the Food Reintroduction phase if a binge-eating dis-
order was identified at the baseline visit and if partici-
pants display issues with eating food while on TDR.
Participants with diabetes receiving the weight-loss as-
pect of the intervention will have blood glucose levels
checked at this visit. A period of at least 1 week should
be left between the end of the intervention and the date
of surgery to facilitate the food reintroduction process.
Participants on the weight-loss programme will be
provided with information on weight-loss maintenance if
not already received.
All services/interventions received in the control group
will be recorded as part of the process evaluation.
Follow-up review (all participants)
A review will be completed in clinic with participants a
minimum of 90 days after the planned date of surgery. A
timed-get-up-and-go test will be performed and partici-
pants will be asked to complete the following question-
naires: WOMAC, OKS, EQ-5D, arthritis self-efficacy,
pain self-efficacy scale, a pain questionnaire and an eat-
ing self-efficacy scale (for those participants receiving
the weight-loss aspect of the intervention). Weight and
blood pressure measurements will be collected from all
participants. Participants who have undertaken the
weight-loss aspect of the study will be asked to complete
a binge-eating scale questionnaire and an eating-
disorder examination questionnaire if a binge-eating dis-
order was identified at the baseline visit and if partici-
pants display issues with eating food while on TDR.
Participants with diabetes that were receiving the
weight-loss aspect of the intervention will have blood
glucose levels checked at this visit.
Participants will also be asked to complete a satisfac-
tion questionnaire at this time point. Data on complica-
tions experienced 90 days after surgery will be collected
at this visit and from the participants’ medical notes.
Process evaluation
All participants (control and intervention arm) will be
invited to participate in an interview at the time of con-
sent. Participants will also be invited to provide consent
to allow recording of study reviews (where the research
nurse is happy to do so) which will be analysed as part
of the process evaluation. Interviews will explore partici-
pants’ attitudes towards the study processes and feasibil-
ity and acceptability of the intervention as well as
assessing barriers and adherence issues. Participants who
refuse to take part in the interview or refuse recording
of study reviews will still be eligible to take part in the
main study. Qualitative interviews will be conducted
with up to 30 participants, sampled purposively across a
range of ages and trial participation status (refused to
participate, agreed and retained to follow-up, agreed but
did not complete the intervention). Interviews with con-
trol and intervention participants will be conducted at
an appropriate time before surgery or during the 90-day
follow-up period. Interviews with individuals who de-
clined participation or withdrew from the study will be
conducted at an appropriate time during the trial period.
All participant reviews will be audio-recorded (where
consent has been provided to do so).
Health care practitioners involved in the delivery of the
intervention will be invited to be interviewed as well as up
to five staff at each of the sites where the intervention is be-
ing delivered. These interviews will be conducted at an ap-
propriate time during the trial period and will be conducted
face to face or by telephone according to the preference of
the interviewee. The qualitative interviews will be facilitated
by a qualitative researcher with input from the qualitative
lead on the study (Professor Sharon Simpson).
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Data collection and storage
See Table 1 for an example schedule of study assess-
ments and time points. Trial data will be collected on
paper data collection sheets and transcribed into the
project database, a web-based data entry system, at site
by the research team. Data will be collected in clinic or
over the telephone by a member of the research team.
Personal data and study data collected on paper forms
will be stored in a locked filing cabinet in a secure loca-
tion at the recruitment centre.
Data regarding complications following surgery (e.g.
deep vein thrombosis (DVT), infections, etc.) will be col-
lected from the hospital records throughout the partici-
pants’ participation in the study to rehearse the data
collection methods for the effectiveness trial. Partici-
pants will also be asked about any problems during the
intervention period reviews, final review (pre-surgery)
and 90-day follow-up visits.
Qualitative data will be collected by audio-recording
and/or on paper forms during study reviews and inter-
views with a subset of participants, health care practi-
tioners involved in delivering the intervention and staff
at the sites where the intervention is being delivered.
Audio data will be recorded using encrypted digital
recording devices (with minimum encryption standard
of AES256 equivalent) and downloaded to password-
protected folders on networked drives at the University
of Glasgow. Recordings will then be deleted off the re-
cording device. Data will be subsequently transcribed (a
third party may be employed to transcribe the data) after
which recordings will be deleted. The qualitative re-
searcher employed to carry out the process evaluation
will be responsible for the secure storage of data.
The trial database will be stored on secure servers at the
University of Edinburgh. This database will have re-
stricted, username- and password-controlled access. A
Data Management Plan will be prepared that will include
the following details as a minimum: CRF development
and management; CRF workflow, data-entry processes
and location of source data; training and user access; data
quality; quality control; and database lock. Additional de-
tails regarding the management of study data may be
added to the Data Management Plan where applicable.
Designated staff at ECTU will follow ECTU Standard Op-
erating Procedures (SOPs) to obtain missing data and re-
solve queries with site staff and to ensure data quality and
completeness of data across sites. A Data Quality Check
Plan will be prepared as a separate document.
Statistics and data analysis
Sample size calculation
Randomised trial (feasibility)
This is a feasibility study and so its aim is to assess the ac-
ceptability and practicality of delivering the intervention,
and to estimate parameters for a larger study. As part of
the feasibility design, we plan a 6-month recruitment win-
dow to estimate the participation rate for the future effect-
iveness trial. In terms of sample size, the choice of 60 is
appropriate to see if a meaningful recruitment rate can be
achieved. This size of feasibility study has been recom-
mended by Lancaster et al. [29]. In terms of looking more
formally at feasibility, a sample of 60 randomised partici-
pants would allow us to estimate proportions such as the
proportion compliant with the different aspects of the
intervention or the proportion completing the trial.
As most participants (estimated to be over 80% from
our pilot data) will require multiple components of the
intervention, the retention outcome relates to the overall
package. Retention within the trial, applicable to all 60
randomised subjects, will be estimated with a standard
error (SE) of approximately 6%. Compliance with the
package of care, applicable to the 40 participants rando-
mised to the intervention group, will be estimated with a
SE of approximately 8%.
Participants will be stratified to ensure that we address
the aim of testing the feasibility of recruiting people with
a range of BMI values.
Qualitative interviews
Qualitative interviews will be conducted with approxi-
mately 30 patients sampled purposively across a range of
ages and trial participation statuses, research staff involved
in the delivery of the intervention and up to five staff at
each of the sites where the intervention is being delivered.
Proposed analyses
As this is a feasibility study the quantitative data will be
presented descriptively, using appropriate summary sta-
tistics with corresponding 95% confidence intervals.
Additionally, the results will be summarised separately
for the two sites, and no formal comparisons will be
made. The key outcome measure is the number of par-
ticipants recruited per centre over the 6-month recruit-
ment period, which will be supported by the preparation
of a Consolidated Standards of Reporting Trials (CON-
SORT) flow chart per centre showing the ‘pipeline leak-
age’ from potentially eligible patients listed for surgery
through to eligible, consented, randomised patients.
Rates of compliance with each relevant component of
the intervention will also be reported along with comple-
tion rates for all outcome measures. The feasibility trial
is not powered to explore efficacy, but the outcome data
will be used to estimate the standard deviation (SD) of
the data for the different outcome scales (especially
WOMAC), and the impact on this SD of baseline adjust-
ment. These estimates of variability will be used to in-
form the sample size calculation for the effectiveness
trial. There are no plans to conduct interim analyses
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while recruitment is on-going or before follow-up is
completed.
In designing this study we have followed the MRC guid-
ance for developing and evaluating complex interventions
[24]. This guidance indicates that rigid progression criteria
are not appropriate. In collaboration with the Trial Steer-
ing Committee (TSC) we shall develop a straightforward
decision model that will identify key barriers and enablers
of recruitment, retention and compliance, and use this to
decide whether and how we can adapt the design to over-
come any problems we encounter.
Qualitative analyses
Qualitative data will be analysed using Braun and Clarks’
approach to thematic analysis [30]. The resulting coding
framework will be discussed within the team to finalise
meaningful themes and sub-themes. Twenty percent of
the interviews will be double coded. Disagreements will
be resolved by discussion. The analyses will test the
hypothesised causal pathways expressed in the logic
model. This will inform the study design of any future
trial by determining which elements of the intervention
work well for health-behaviour change in participants,
how they interact with each other and which need ad-
justment or further development.
The audio-recordings of sessions will be analysed using a
checklist developed as part of the process evaluation. The
researchers will listen to the audio-recordings and code ab-
sence or presence of different core parts of the intervention
for the purposes of checking intervention fidelity.
Key cost-driver analysis
Identification of key cost drivers will be done through
consultations with local experts to discuss the types of
NHS services expected to be major and minor drivers
differences in costs in patients undertaking the interven-
tion or standard care. This will include consultation with
the lead health economist (Andrew Stoddart), working
on the analysis of NHS costs of the TRIO physio trial (a
trial of physiotherapy for patients with poorly perform-
ing knee transplants, CI: Hamish Simpson). This trial in-
cluded a baseline self-reported NHS resource survey at
6 weeks post surgery profiling service use in the preced-
ing 3 months. These results will be visually inspected to
identify factors which appear to constitute most substan-
tially to total cost figures in order to inform future sur-
vey design. Any other transferable lessons from the trial
will also be documented.
Additional information
Oversight and safety reporting
The study is sponsored by the Academic and Clinical
Central Office for Research and Development – Joint
Office for The University of Edinburgh and Lothian
Health Board (ACCORD) and relevant SOPs have
been applied to this study. Safety reporting will be
conducted in line with relevant sponsor SOPs. Study-
specific particulars are detailed in the complete trial
protocol. A Trial Management Group and a TSC has
been established.
Confidentiality and data protection
All evaluation forms, reports, and other records must be
identified in a manner designed to maintain participant
confidentiality. All records must be kept in a secure stor-
age area with limited access. Clinical information will
not be released without the written permission of the
participant. The Investigator and study site staff involved
with this study may not disclose or use for any purpose
other than performance of the study, any data, record,
or other unpublished, confidential information disclosed
to those individuals for the purpose of the study. Prior
written agreement from the sponsor or its designee must
be obtained for the disclosure of any said confidential in-
formation to other parties.
All Investigators and study site staff involved with this
study must comply with the requirements of the Data
Protection Act 1998 with regard to the collection, stor-
age, processing and disclosure of personal information
and will uphold the Act’s core principles. Access to col-
lated participant data will be restricted to individuals
from the research team treating the participants, repre-
sentatives of the sponsor(s) and representatives of regu-
latory authorities.
Computers used to collate the data will have limited
access measures via user names and passwords.
Published results will not contain any personal data
that could allow identification of individual participants.
Authorship policy and publication
Ownership of the data arising from this study resides
with the Trial Management Group. On completion of
the study, the study data will be analysed and tabulated
and a clinical study report prepared in accordance with
International Conference on Harmonisation (ICH)
guidelines. A separate publication policy will be prepared
for the study.
The clinical study report will be used for publication
and presentation at scientific meetings. Summaries of re-
sults will be made available to Investigators for dissemin-
ation within their clinics (where appropriate and
according to their discretion).
Discussion
The aims of the study specifically relate to testing the
feasibility and acceptability of the proposed effectiveness
trial intervention and the feasibility of the trial methods.
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We will recruit patients recently added to the waiting
list for knee replacement surgery, aiming to take advan-
tage of the incentive for behaviour change in these pa-
tients. Patients will be randomised to receive a package
of care which incorporates behaviour-change strategies
to help people to change their behaviour initially and
maintain this in the longer term, particularly in relation
to the four elements of the intervention. We postulate
that a reduction in weight and increased activity coupled
with an appropriate analgesia review and attention to
footwear in the pre-operative window will result in a
sustained improvement in the patient’s health-related
quality of life following knee replacement.
This study forms the important first step in developing
and assessing whether the intervention has potential to
be assessed in a future fully powered effectiveness trial.
The findings will also be used to refine the design of the
effectiveness trial.
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